Ozempic reduces knee osteoarthritis pain by almost half: Study
The results of a clinical trial published this week found that the active ingredient in the diabetes and weight loss medications Ozempic and Wegovy was linked with a near halving of reported pain among patients with knee osteoarthritis and obesity.
The study funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy, involved 407 participants taking either the active ingredient semaglutide or a placebo for 68 weeks. Roughly 82 percent of participants were women.
To measure pain, researchers used the Western Ontario and McMaster Universities Arthritis Index (WOMAC). The WOMAC involves participants scoring pain, difficulty and physical function when doing everyday activities like walking up and down stairs or sitting.
At the start of the trial, the average WOMAC pain score among participants was 70.9. By the 68th week, those taking semaglutide reported an average WOMAC pain score of 29.2, while those taking a placebo reported an average pain score of 43.4.
The semaglutide participants on average had a body weight reduction of 13.7 percent, while those taking a placebo had a 3.2 percent reduction on average.
"Among participants with obesity and knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis than placebo," the study's conclusion stated.
As the Johns Hopkins Arthritis Center notes, overweight women have almost four times the risk of developing knee osteoarthritis when compared to non-obese women. For obese men, the risk is five times higher than their non-obese counterparts.
GLP-1 agonists like semaglutide have been explored for uses beyond obesity and diabetes. Semaglutide has been studied for potential benefits for treating addiction, kidney failure, liver disease and early Alzheimer’s disease.
Topics
-
Ozempic and Wegovy Ease Knee Osteoarthritis Pain in Large Study
Health - The New York Times - Yesterday -
Semaglutide linked to reduced arthritis knee pain in people with obesity, study finds
Top stories - NBC News - Yesterday -
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
Business - CNBC - October 24 -
Study finds drugs like Ozempic could help with substance addiction
Top stories - CBS News - October 17 -
Climate crisis caused half of European heat deaths in 2022, says study
World - The Guardian - 2 days ago -
Weight-loss drugs may reduce opioid and alcohol abuse by up to 50%, study finds
Business - MarketWatch - October 19 -
Drugmaker wants an end to Ozempic copies
Politics - The Hill - October 23 -
Ozempic lowers Alzheimer’s risk: Research
Politics - The Hill - October 24 -
Tips to Reduce Halloween Waste
World - The New York Times - October 22
More from The Hill
-
Shapiro calls Vance's Pennsylvania voter fraud claim 'bull----'
Politics - The Hill - 1 hour ago -
Trump: RFK Jr. will work on 'health and women's health'
Politics - The Hill - 1 hour ago -
Raffensperger asks X to take down 'false' video purporting to show voter fraud
Politics - The Hill - 2 hours ago -
Emhoff on Trump’s personal attacks of Harris: ‘As a husband, it pisses me off’ but ‘we cannot be distracted by it’
Politics - The Hill - 2 hours ago -
Walz to deliver closing message on 'The Late Show with Stephen Colbert'
Politics - The Hill - 2 hours ago
Latest in Politics
-
Shapiro calls Vance's Pennsylvania voter fraud claim 'bull----'
Politics - The Hill - 1 hour ago -
Trump: RFK Jr. will work on 'health and women's health'
Politics - The Hill - 1 hour ago -
Raffensperger asks X to take down 'false' video purporting to show voter fraud
Politics - The Hill - 2 hours ago -
Emhoff on Trump’s personal attacks of Harris: ‘As a husband, it pisses me off’ but ‘we cannot be distracted by it’
Politics - The Hill - 2 hours ago -
Walz to deliver closing message on 'The Late Show with Stephen Colbert'
Politics - The Hill - 2 hours ago